Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/52568
Title: Unique cardiometabolic factors in women that contribute to modified cardiovascular disease risk.
Authors: Hetherington K.;Thomas J.;Nicholls S.J.;Barsha G.;Bubb K.J.
Monash Health Department(s): Cardiology (MonashHeart)
Institution: (Hetherington, Thomas, Barsha, Bubb) Biomedicine Discovery Institute, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, 3800, Australia; Victorian Heart Institute, Victorian Heart Hospital, Clayton, Victoria, 3168, Australia
(Nicholls) Victorian Heart Institute, Victorian Heart Hospital, Clayton, VIC 3168, Australia
Issue Date: 11-Oct-2024
Copyright year: 2024
Place of publication: Netherlands
Publication information: European Journal of Pharmacology. (pp 177031), 2024. Date of Publication: 04 Oct 2024.
Journal: European Journal of Pharmacology.
Abstract: Major risk factors of cardiovascular disease (CVD) include hypertension, obesity, diabetes mellitus and metabolic syndrome; all of which are considered inflammatory conditions. Women are disproportionately affected by inflammatory conditions, with sex differences emerging as early as adolescence. Hormonal fluctuations associated with reproductive events such as menarche, pregnancy and menopause, are hypothesized to promote a pro-inflammatory state in women. Moreover, women who have experienced inflammatory-type conditions such as polycystic ovarian syndrome (PCOS), gestational diabetes or pre-eclampsia, have a cardiometabolic phenotype that pre-disposes to increased risk of myocardial infarction, stroke and coronary heart disease. Women with no notable CVD risk factors are often relatively protected from CVD pre-menopause; but overtake men in risk of major cardiovascular events when the cardiovascular protective effects of oestrogen begin to wane. Sex differences and female-specific factors have long been considered challenging to study and this has led to an underrepresentation of females in clinical trials and lack of female-specific data from pre-clinical studies. However, there is now a clear prerogative to include females at all stages of research, despite inherent complexities and potential variability in data. This review explores recent advancements in our understanding of CVD in women. We summarise the underlying factors unique to women that can promote CVD risk factors, ultimately contributing to CVD burden and the emerging therapies aimed to combat this.Copyright © 2024. Published by Elsevier B.V.
DOI: http://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1016/j.ejphar.2024.177031
PubMed URL: 39369878 [https://www.ncbi.nlm.nih.gov/pubmed/?term=39369878]
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/52568
Type: Article
Subjects: blood pressure
cardiovascular disease
cardiovascular risk
cerebrovascular accident
diabetes mellitus
gestational diabetes
heart disease
hypertension
inflammatory disease
menarche
menopause
metabolic syndrome X
ovary disease
ovary polycystic disease
preeclampsia
premenopause
Type of Clinical Study or Trial: Review article (e.g. literature review, narrative review)
Appears in Collections:Articles

Show full item record

Page view(s)

4
checked on Oct 23, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.